PROCEPT BioRobotics (PRCT) investor relations material

Market opportunity and growth strategy

• Only 10% penetrated into a 400,000-patient annual procedure market, with significant headroom for share gains and expansion into an 8 million patient drug-therapy population and a broader 40 million with BPH.

• Procedure growth is accelerating, with over 125,000 patients treated globally and more than 900 instruments installed, with plans to add 200+ systems in the next year.

• Commercial realignment, dedicated launch teams, and targeted education are driving faster adoption and improved execution.

• Greenfield placements and alternative capital acquisition strategies, including leasing pilots, are expanding access to new customer groups.

• Strategic shift to eliminate end-of-quarter discounts, resulting in higher ASPs and more predictable ordering patterns.

Organizational and commercial changes

• Sales, clinical, and capital teams integrated under regional leadership to optimize resource allocation and accelerate launches.

• Launch teams now under capital, reducing time from PO to first 10 cases by 50% in pilot, aiming for rapid, healthy program launches.

• Realignment of territories and backfilling of procedure teams expected to cause short-term disruption but drive long-term benefits.

• Replacement strategy for legacy systems introduced, with trade-in credits and a focus on converting the installed base to HYDROS.

• Aquablation is trending toward becoming the leading modern surgical BPH treatment, closing the gap with TURP.

Clinical evidence and product differentiation

• Aquablation is supported by robust clinical evidence, including multiple randomized trials and real-world studies, demonstrating durable symptom relief, low reoperation rates, and preservation of sexual and urinary function.

• Aggregated data from 18 publications show <1% rates of incontinence and erectile dysfunction, and a low transfusion rate across a wide range of prostate sizes.

• Category I reimbursement achieved, removing prior reimbursement uncertainty.

• The HYDROS system, an AI-enabled robotic platform, is being launched globally and is expected to represent the majority of the install base by the end of 2026.

• Marketing focus on aligning physician and patient priorities, addressing low patient awareness (currently 1%-2%), and targeted education at decision points.